Your session is about to expire
← Back to Search
CFT8634 for Advanced Sarcoma
Study Summary
This trial is testing a new drug for people with cancer who have had other treatments that didn't work and can't have any other treatments that are known to help.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken medication called BRD9 degrader before.You have had another type of cancer in the past 3 years that is still growing or needed treatment.If you have had certain types of skin cancer or early stage breast or cervical cancer that have been treated successfully, you can still participate.You have a condition that affects how your body absorbs nutrients from food, like malabsorption syndrome.You have a type of cancer called synovial sarcoma or SMARCB1-null solid tumor that has come back, is not responding to treatment, and has spread to other parts of your body. You cannot receive any other treatments that have been proven to help.
- Group 1: Dose Escalation Phase 1/Part1: CFT8634
- Group 2: Dose Escalation Phase 1/Part 2: CFT8634
- Group 3: Phase 2 - Arm B: CFT8634
- Group 4: Phase 2 - Arm A: CFT8634
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widely is this clinical experiment being conducted within the state?
"Currently, 10 medical centres are recruiting participants for this trial. These locations span Aurora, Duarte and New york City; other nearby cities also offer sites to enrol in the study. To reduce travel needs, it is wise to select a facility close by your home or work location."
Are researchers currently seeking participants for this trial?
"Affirmative. According to clinicaltrials.gov, this experiment was initially advertised on March 25th 2022 and recently modified on September 26th of the same year; it currently requires 110 participants spread across 10 different sites."
How many participants are actively engaged in this research endeavor?
"C4 Therapeutics, Inc. is responsible for facilitating the clinical trial and has determined that 110 qualified participants are needed to proceed with data collection. The study will be conducted in two locations: University of Colorado - Aurora Cancer Center in Aurora,Colorado and City of Hope in Duarte, California."
What results is this trial designed to produce?
"This clinical trial intends to evaluate the frequency and intensity of adverse events (AEs) and serious adverses events (SAEs) over a period extending from enrolment until at least 30 days after completion of treatment. Secondary endpoints include assessing the percent reduction in tumour BRD9 degradation, characterizing CFT8634's pharmacokinetics parameters through plasma concentration monitoring, and measuring DOR - defined as time from first assessment of PR or CR to follow-on first assessment of progressive disease (PD)."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger